# Avidity Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avidity-biosciences

- Industry: Biotechnology
- Headquarters: US
- Website: www.aviditybiosciences.com
- Total disclosed funding: $126M
- Latest round: Series C (Nov 13, 2019)
- Investors on record: 19

## About

Avidity Biosciences is focused on developing targeted RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugates (AOC™) platform, addressing serious muscle diseases and advancing innovative treatments.Founded in 2013, Avidity Biosciences is dedicated to the development of RNA therapeutics. The company is headquartered in the US and has undergone strategic developments, including a recent funding round. Sarah Boyce serves as the CEO. Avidity Biosciences specializes in creating a new class of targeted RNA therapeutics through its AOC™ platform, which combines monoclonal antibodies with oligonucleotides. The company aims to treat muscle diseases such as myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy. Products are developed for North American markets, with potential expansion into Europe and Asia. The revenue model is based on partnerships and collaborations with pharmaceutical companies, involving milestone payments and royalties from the commercialization of its AOC™ platform and therapeutic candidates. In October 2025, Novartis International AG, agreed to fully acquire Avidity Biosciences, Inc from F-Prime Capital, TPG Biotech,Tavistock Group,Moore Venture Partners for USD 12 billion.

## Funding rounds

- Series C, Nov 13, 2019, $101M — Alexandria Venture Investments, Takeda Ventures, Eli Lilly & Company, RTW Investments, EcoR1 Capital, Cormorant Asset Management, Partner Fund Management, Alethea Capital Management, Perceptive Advisors, Boxer Capital, Brace Pharma Capital, Logos Capital, STPharm, CureDuchenne Ventures
- Series B, Jan 5, 2017, $10M — Alexandria Venture Investments, F-Prime Capital, Tavistock Group, Moore Venture Partners, Takeda Ventures, EcoR1 Capital, Alethea Capital Management, Brace Pharma Capital
- Series B, Oct 7, 2014, $6M — F-Prime Capital, TPG Biotech, Brace Pharmaceuticals, Partner Fund Management, Alethea Capital Management
- Series A, Feb 18, 2014, $9.1M — Alethea Capital Management

## Investors

- Alethea Capital Management (https://capitalatlas.ai/funds/alethea-capital-management) — Series A, Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series B
- Brace Pharmaceuticals — Series B
- Partner Fund Management — Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B, Series C
- Tavistock Group (https://capitalatlas.ai/funds/tavistock-group) — Series B
- Moore Venture Partners (https://capitalatlas.ai/funds/moore-venture-partners) — Series B
- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B, Series C
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B, Series C
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series B, Series C
- Eli Lilly & Company — Series C
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series C
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series C
- STPharm — Series C
- CureDuchenne Ventures (https://capitalatlas.ai/funds/cureduchenne-ventures) — Series C